Polyrizon files European patent application for drug delivery platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
April 27, 2026 9:28 AM EDTRaanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the Company or Polyrizon), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Europe Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Companys advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Companys recently announced U.S. patent application which... More
